Intra-Cellular Therapies, Inc. (ITCI) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in New York City, NY, United States. The current CEO is Sharon Mates.
ITCI has IPO date of 2014-01-07, 860 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $14.05B.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company headquartered in New York that develops novel medications for neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms in the central nervous system. The company's approved product CAPLYTA treats schizophrenia in adults, while its clinical pipeline includes lumateperone in Phase III trials for bipolar depression and autism spectrum disorder, Lenrispodun for Parkinson's disease and heart failure, ITI-1284-ODT-SL for dementia-related behavioral disturbances, and ITI-333 for substance use disorders and psychiatric conditions. Founded in 2002, the company focuses on addressing significant unmet medical needs in the neuropsychiatric market through innovative drug development.
